Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke

Peter A G Sandercock, Carl Edward Counsell, Mei-Chiun Tseng

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

BACKGROUND: Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. This is an updated version of the original Cochrane review first published in Issue 1, 1995 and previously updated in Issue 2, 2005. OBJECTIVES: To compare the effects of low-molecular-weight heparins or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (last searched June 2007). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (1966 to June 2007) and EMBASE (1980 to June 2007). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies. SELECTION CRITERIA: Randomised trials comparing heparinoids or low-molecular-weight heparins with standard unfractionated heparin in people with acute ischaemic stroke. We only included trials where treatment was started within 14 days of stroke onset. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, assessed trial quality and extracted the data. MAIN RESULTS: Nine trials involving 3137 people were included. Four trials compared a heparinoid (danaparoid), four trials compared low-molecular-weight heparin (enoxaparin or certoparin), and one trial compared an unspecified low-molecular-weight heparin with standard unfractionated heparin. Allocation to low-molecular-weight heparin or heparinoid was associated with a significant reduction in the odds of deep vein thrombosis compared with standard unfractionated heparin (odds ratio (OR) 0.55, 95% confidence interval (CI) 0.44 to 0.70). However, the number of more major events (pulmonary embolism, death, intracranial or extracranial haemorrhage) was too small to provide a reliable estimate of the benefits and risks of low-molecular-weight heparins or heparinoids compared with standard unfractionated heparin for these, arguably more important, outcomes. Insufficient information was available to assess effects on recurrent stroke or functional outcome. AUTHORS' CONCLUSIONS: Since the last version of this review none of the three new relevant studies with 2397 participants have provided additional information to change the conclusions. Treatment with a low-molecular-weight heparin or heparinoid after acute ischaemic stroke appears to decrease the occurrence of deep vein thrombosis compared with standard unfractionated heparin, but there are too few data to provide reliable information on their effects on other important outcomes, including death and intracranial haemorrhage.
Original languageEnglish
Article numberCD000119
JournalCochrane Database of Systematic Reviews
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Heparinoids
Low Molecular Weight Heparin
Heparin
Stroke
Venous Thrombosis
Hemorrhage
Enoxaparin
Intracranial Hemorrhages
Pulmonary Embolism
MEDLINE
Anticoagulants
Libraries
Odds Ratio
Confidence Intervals

Keywords

  • Anticoagulants
  • Brain Ischemia
  • Fibrinolytic Agents
  • Heparin
  • Heparin, Low-Molecular-Weight
  • Heparinoids
  • Humans
  • Randomized Controlled Trials as Topic
  • Stroke

Cite this

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. / Sandercock, Peter A G; Counsell, Carl Edward; Tseng, Mei-Chiun.

In: Cochrane Database of Systematic Reviews, No. 3, CD000119, 2008.

Research output: Contribution to journalArticle

@article{3159689d6ef54a998b37e4b49bc17fa4,
title = "Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke",
abstract = "BACKGROUND: Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. This is an updated version of the original Cochrane review first published in Issue 1, 1995 and previously updated in Issue 2, 2005. OBJECTIVES: To compare the effects of low-molecular-weight heparins or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (last searched June 2007). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (1966 to June 2007) and EMBASE (1980 to June 2007). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies. SELECTION CRITERIA: Randomised trials comparing heparinoids or low-molecular-weight heparins with standard unfractionated heparin in people with acute ischaemic stroke. We only included trials where treatment was started within 14 days of stroke onset. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, assessed trial quality and extracted the data. MAIN RESULTS: Nine trials involving 3137 people were included. Four trials compared a heparinoid (danaparoid), four trials compared low-molecular-weight heparin (enoxaparin or certoparin), and one trial compared an unspecified low-molecular-weight heparin with standard unfractionated heparin. Allocation to low-molecular-weight heparin or heparinoid was associated with a significant reduction in the odds of deep vein thrombosis compared with standard unfractionated heparin (odds ratio (OR) 0.55, 95{\%} confidence interval (CI) 0.44 to 0.70). However, the number of more major events (pulmonary embolism, death, intracranial or extracranial haemorrhage) was too small to provide a reliable estimate of the benefits and risks of low-molecular-weight heparins or heparinoids compared with standard unfractionated heparin for these, arguably more important, outcomes. Insufficient information was available to assess effects on recurrent stroke or functional outcome. AUTHORS' CONCLUSIONS: Since the last version of this review none of the three new relevant studies with 2397 participants have provided additional information to change the conclusions. Treatment with a low-molecular-weight heparin or heparinoid after acute ischaemic stroke appears to decrease the occurrence of deep vein thrombosis compared with standard unfractionated heparin, but there are too few data to provide reliable information on their effects on other important outcomes, including death and intracranial haemorrhage.",
keywords = "Anticoagulants, Brain Ischemia, Fibrinolytic Agents, Heparin, Heparin, Low-Molecular-Weight, Heparinoids, Humans, Randomized Controlled Trials as Topic, Stroke",
author = "Sandercock, {Peter A G} and Counsell, {Carl Edward} and Mei-Chiun Tseng",
year = "2008",
doi = "10.1002/14651858.CD000119.pub3",
language = "English",
journal = "Cochrane Database of Systematic Reviews",
issn = "1469-493X",
publisher = "Wiley",
number = "3",

}

TY - JOUR

T1 - Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke

AU - Sandercock, Peter A G

AU - Counsell, Carl Edward

AU - Tseng, Mei-Chiun

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. This is an updated version of the original Cochrane review first published in Issue 1, 1995 and previously updated in Issue 2, 2005. OBJECTIVES: To compare the effects of low-molecular-weight heparins or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (last searched June 2007). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (1966 to June 2007) and EMBASE (1980 to June 2007). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies. SELECTION CRITERIA: Randomised trials comparing heparinoids or low-molecular-weight heparins with standard unfractionated heparin in people with acute ischaemic stroke. We only included trials where treatment was started within 14 days of stroke onset. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, assessed trial quality and extracted the data. MAIN RESULTS: Nine trials involving 3137 people were included. Four trials compared a heparinoid (danaparoid), four trials compared low-molecular-weight heparin (enoxaparin or certoparin), and one trial compared an unspecified low-molecular-weight heparin with standard unfractionated heparin. Allocation to low-molecular-weight heparin or heparinoid was associated with a significant reduction in the odds of deep vein thrombosis compared with standard unfractionated heparin (odds ratio (OR) 0.55, 95% confidence interval (CI) 0.44 to 0.70). However, the number of more major events (pulmonary embolism, death, intracranial or extracranial haemorrhage) was too small to provide a reliable estimate of the benefits and risks of low-molecular-weight heparins or heparinoids compared with standard unfractionated heparin for these, arguably more important, outcomes. Insufficient information was available to assess effects on recurrent stroke or functional outcome. AUTHORS' CONCLUSIONS: Since the last version of this review none of the three new relevant studies with 2397 participants have provided additional information to change the conclusions. Treatment with a low-molecular-weight heparin or heparinoid after acute ischaemic stroke appears to decrease the occurrence of deep vein thrombosis compared with standard unfractionated heparin, but there are too few data to provide reliable information on their effects on other important outcomes, including death and intracranial haemorrhage.

AB - BACKGROUND: Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. This is an updated version of the original Cochrane review first published in Issue 1, 1995 and previously updated in Issue 2, 2005. OBJECTIVES: To compare the effects of low-molecular-weight heparins or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (last searched June 2007). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (1966 to June 2007) and EMBASE (1980 to June 2007). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies. SELECTION CRITERIA: Randomised trials comparing heparinoids or low-molecular-weight heparins with standard unfractionated heparin in people with acute ischaemic stroke. We only included trials where treatment was started within 14 days of stroke onset. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, assessed trial quality and extracted the data. MAIN RESULTS: Nine trials involving 3137 people were included. Four trials compared a heparinoid (danaparoid), four trials compared low-molecular-weight heparin (enoxaparin or certoparin), and one trial compared an unspecified low-molecular-weight heparin with standard unfractionated heparin. Allocation to low-molecular-weight heparin or heparinoid was associated with a significant reduction in the odds of deep vein thrombosis compared with standard unfractionated heparin (odds ratio (OR) 0.55, 95% confidence interval (CI) 0.44 to 0.70). However, the number of more major events (pulmonary embolism, death, intracranial or extracranial haemorrhage) was too small to provide a reliable estimate of the benefits and risks of low-molecular-weight heparins or heparinoids compared with standard unfractionated heparin for these, arguably more important, outcomes. Insufficient information was available to assess effects on recurrent stroke or functional outcome. AUTHORS' CONCLUSIONS: Since the last version of this review none of the three new relevant studies with 2397 participants have provided additional information to change the conclusions. Treatment with a low-molecular-weight heparin or heparinoid after acute ischaemic stroke appears to decrease the occurrence of deep vein thrombosis compared with standard unfractionated heparin, but there are too few data to provide reliable information on their effects on other important outcomes, including death and intracranial haemorrhage.

KW - Anticoagulants

KW - Brain Ischemia

KW - Fibrinolytic Agents

KW - Heparin

KW - Heparin, Low-Molecular-Weight

KW - Heparinoids

KW - Humans

KW - Randomized Controlled Trials as Topic

KW - Stroke

U2 - 10.1002/14651858.CD000119.pub3

DO - 10.1002/14651858.CD000119.pub3

M3 - Article

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 3

M1 - CD000119

ER -